Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 6/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 6/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | PAK4 | O96013 | 1/20 | 0.35 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020769 | 1.00 | SPHK2 (0.37) | SPHK2SPHK1HRH3CHRM1MCHR1 | |
| SCHEMBL12574478 | 0.85 | SPHK1 (0.39) | SPHK2SPHK1HRH3CHRM1MCHR1 | |
| SCHEMBL1024989 | 0.82 | HRH3 (0.41) | HRH3CDK2 | |
| SCHEMBL12635793 | 0.81 | SLC6A9 (0.36) | — | |
| SCHEMBL1023537 | 0.80 | MYC (0.35) | CDK2MYCWDR5 | |
| SCHEMBL2025538 | 0.78 | LTA4H (0.44) | — | |
| SCHEMBL2025542 | 0.78 | LTA4H (0.44) | — | |
| SCHEMBL2023377 | 0.76 | KDM4E (0.41) | HRH3 | |
| SCHEMBL2023375 | 0.76 | KDM4E (0.41) | HRH3 | |
| SCHEMBL1347559 | 0.74 | ALOX15 (0.48) | HRH3CDK2MYCWDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452977-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| US-8946440-B2 | Cyclopentylacrylamide derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2015-02-03 | — | — | US | disclosed |
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | TEIJIN LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160211-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | SPHK2 928/4885SPHK1 440/4885HRH3 3240/4885 |
| US-20150105581-A1 | CYCLOPENTYLACRYLAMIDE DERIVATIVE | GPR119, SLC5A1, SLC5A2 | SPHK2 928/4885SPHK1 440/4885HRH3 3240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.